Suraksha Diagnostics launches genomics lab in eastern India with ₹22 crore investment

Suraksha Diagnostics has inaugurated a genomics laboratory in Kolkata, marking one of the largest such facilities in Eastern India. The lab was officially launched in the presence of Prof Sukumar Mukherjee, a senior rheumatologist and mentor at Suraksha Diagnostics.

Located in West Bengal, the genomics facility reflects the region’s current growth in medical services and education. Suraksha Diagnostics stated that the lab addresses the increasing need for accessible genomic diagnostics in the state, aligning with broader developments in preventive healthcare and risk-based diagnostics.

According to market projections, the global genetic testing sector is valued at USD 38.77 billion in 2024 and is estimated to reach USD 186.64 billion by 2035, growing at a CAGR of 22.5 per cent. Suraksha Diagnostics has invested ₹22 crore in the facility and plans an additional ₹46 crore investment over the next two years to further expand capabilities, aiming to establish one of Asia’s most advanced genomics laboratories.

The laboratory houses technologies including cytogenetics, microarray, Sanger sequencing, and multiple next-generation sequencing (NGS) platforms. These systems collectively support a wide range of genetic testing, applicable to predictive, preventive, and personalised care.

Suraksha’s genomics lab provides prenatal genetic screening for chromosomal abnormalities such as Down syndrome, Edwards syndrome, Patau syndrome, and other chromosomal disorders. These services are supported by genetic counselling to aid informed decision-making for expecting families.

The facility also offers oncology diagnostics through hereditary cancer panels that assist in detecting genetic predispositions to cancers including breast, ovarian, and colorectal. The lab provides germline and somatic mutation profiling and offers targeted oncology panels using NGS, which enable precision-based treatment strategies.

Diagnostic methods at the lab begin with karyotyping to analyse all chromosomes, followed by chromosomal microarray for identifying smaller genetic anomalies. FISH (Fluorescence in situ Hybridisation) is used to pinpoint specific genetic conditions, while Sanger sequencing is applied for individual gene reading. NGS provides deeper genomic insights by scanning large volumes of genetic data.

Commenting on the launch, Dr Somnath Chatterjee, Chairman and Joint Managing Director at Suraksha Diagnostics, said, “A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics—unlocking the secrets of the Human Genome, enabling early diagnosis, predictive analytics, and personalised treatments. From Fetal Medicine to Oncology and Rare Diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostics is proud to be at the forefront of this revolution.”

Ritu Mittal, CEO and Managing Director at Suraksha Diagnostics, said, “We provide end-to-end solution for prenatal genetics, offering comprehensive testing facilities. We aim to be a premium, aspirational choice for clinicians and families seeking the highest standards in fetal, reproductive, paediatric and onco-genetics without the need to send samples out of the region or compromise on quality.”